Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Stopped Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study prior to enrollment of any patients.

Conditions

• Diffuse Large B Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Grey Zone Lymphoma
• High Grade B Cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Interventions

• DRUG: Brentuximab
• DRUG: Bendamustine
• DRUG: Rituximab

Sponsor

University of Arizona